Last reviewed · How we verify
NCT02736357: LEO
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
trial in Non-Hodgkin Lymphoma. Withdrawn.
17 April 2023
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 July 2015 |
| Primary completion | 17 April 2023 |
| Estimated completion | 17 April 2023 |
| Sites | 8 locations across United States |
Conditions studied
- Non-Hodgkin Lymphoma — all drugs for Non-Hodgkin Lymphoma →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this infrastructure grant is to establish and maintain a cohort of over 12,000 non-Hodgkin lymphoma (NHL) patients to support broad and cutting-edge research that identifies clinical (including co-morbid diseases), epidemiologic (including lifestyle and other exposures), host genetic, tumor, and treatment factors, as well as the interaction among these factors, on short and long-term outcomes. These efforts will identify new approaches to improve the survival and well-being of NHL patients.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Casulo C, Larson MC, Lunde JJ, Habermann TM, et al · · 2022 · cited 49× · PMID 35358443 · DOI 10.1016/s2352-3026(22)00033-3 -
Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Khurana A, Mwangi R, Nowakowski GS, Habermann TM, et al · · 2021 · cited 30× · PMID 33529046 · DOI 10.1200/jco.20.01935 -
Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.
Lee MJ, Koff JL, Switchenko JM, Jhaney CI, et al · · 2020 · cited 29× · PMID 32469082 · DOI 10.1002/cncr.32866 -
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes.
Cerhan JR, Maurer MJ, Link BK, Feldman AL, et al · · 2024 · cited 21× · PMID 38217361 · DOI 10.1002/ajh.27202 -
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.
Ghesquières H, Rossi C, Cherblanc F, Le Guyader-Peyrou S, et al · · 2021 · cited 15× · PMID 33653294 · DOI 10.1186/s12889-021-10433-4 -
Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.
Yamshon S, Koff JL, Larson MC, Kahl BS, et al · · 2025 · cited 7× · PMID 39918101 · DOI 10.1002/ajh.27630 -
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium.
Day JR, Larson MC, Durani U, Koff JL, et al · · 2025 · cited 7× · PMID 39602301 · DOI 10.1182/bloodadvances.2024014053 -
Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL.
Khurana A, Mwangi R, Nastoupil LJ, Reagan PM, et al · · 2024 · cited 6× · PMID 38991126 · DOI 10.1182/bloodadvances.2024012838
Verify or expand the search:
- PubMed search for NCT02736357
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07284927 — Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies · Phase 1 · recruiting
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT07260812 — KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1 · recruiting
- NCT06915246 — A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma · Phase 2 · recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02736357 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 22 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02736357.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing